Matthew Lang spent months putting together one of the biggest bets in obesity drug history. Now he's working on the pill that might make it obsolete.
Structure Therapeutics announced Tuesday that Lang, the former Chief Legal Officer at Metsera, has joined as Chief Operating Officer and General Counsel. His most recent job was guiding Metsera through its acquisition by Pfizer, a deal worth up to $11 billion according to deal-data provider DCAT Value Chain, with the company's own press release citing up to $10 billion, after Pfizer outbid Novo Nordisk's offer of $65.60 per share with an $86.25 bid. The deal gave Pfizer a path into the GLP-1 obesity market at the precise moment its own injectable programs were falling apart.
Lang's portfolio at Structure includes aleniglipron, an oral GLP-1, meaning a daily pill that mimics the same gut hormone targeted by blockbuster injectable drugs like Ozempic and Wegovy. In a Phase II trial, aleniglipron produced 16.3% weight loss, a figure unusual for a pill, since injectables typically dominate the efficacy charts. Structure plans to move it into Phase III in the second half of 2026.
Pfizer acquired Metsera because it had no choice. The company had discontinued two internal GLP-1 candidates, lotiglipron in 2023 and danuglipron in April 2025, leaving it with a massive market and no product. The Metsera acquisition was the fastest path to a credibly competitive position, paying a steep premium for speed. With aleniglipron, Structure is betting that premium was paid for the wrong horse.
The oral GLP-1 field is now one of the most crowded in biotech. Eli Lilly's orforglipron is already approved and in Phase III. Novo Nordisk is developing oral semaglutide, the pill version of its flagship injection. Structure's aleniglipron will enter a Phase III arena where competitors have longer track records, more trial infrastructure, and established relationships with regulators and prescribers. The 16.3% weight loss figure, while notable for an oral drug, comes from a Phase II trial in a controlled setting. Phase III will test whether that result holds across a broader patient population, at multiple doses, with the operational rigor the FDA requires.
Structure has never run a Phase III trial. The company was founded in 2022 and went public in 2023. Building Phase III operational infrastructure, sites, enrollment, data management, regulatory submissions, is a fundamentally different challenge than running a Phase II study, and the timeline for aleniglipron's first Phase III readout is 2028 at the earliest, based on the company's stated plans.
If aleniglipron succeeds, the implications for Pfizer are significant but not immediate. Metsera brings injectable candidates with established manufacturing and a clear regulatory path, assets that will generate revenue regardless of what happens with oral GLP-1s. Pfizer is not betting solely on the injectable future. It is hedging across multiple modalities. But whether the oral GLP-1 market grows large enough to commoditize the injectable space, or whether the two coexist in separate patient segments, remains an open question.
Lang's move from the acquiring side to the competing side adds a layer the market has noticed. He knows which assumptions built the Metsera valuation. He knows what Pfizer was trying to protect. And he is now at the company trying to stress-test exactly those assumptions.
Aleniglipron's Phase III will be one of the more closely watched obesity trials of the next few years, not because it is likely to dislodge the leaders, but because it will answer a question the whole field is watching: does a pill with competitive efficacy exist, and if so, what happens to the companies that paid heavily for their injectable head start.
Structure Therapeutics announcement | Phase II aleniglipron data | Pfizer/Metsera deal terms | Orforglipron FDA approval